Morgan Stanley analyst Cecilia Furlong maintains Intuitive Surgical (NASDAQ:ISRG) with a Equal-Weight and lowers the price target from $330 to $300.
Morgan Stanley lowers Intuitive Surgical (NASDAQ:ISRG) price target from $330 to $300 Read Post »
Citigroup analyst Andrew Baum maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $525 to $675.
Citigroup raises Eli Lilly (NYSE:LLY) price target from $525 to $675 Read Post »
Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS (sotorasib) (960 mg or 240 mg) in combination with Vectibix (panitumumab). Both doses demonstrated a statistically significant superiority in progression-free survival (PFS) over the investigator’s choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). The results are being presented today at the Presidential Symposium 2 session as a late-breaking oral presentation (LBA10) during the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, with simultaneous publication in the New England Journal of Medicine. “The CodeBreaK 300 trial demonstrated the benefit of LUMAKRAS plus Vectibix to deliver statistically significant PFS outcomes for patients compared to the investigator’s choice of therapy, offering new hope to this population with historically poor outcomes,” said David M. Reese, M.D., executive vice president, Research and Development at Amgen.
Intuitive Surgical (ISRG) reported late Thursday Q3 non-GAAP earnings of $1.46 per diluted share, up from $1.19 a year earlier. Analysts polled by Capital IQ expected $1.42. Revenue for the quarter ended Sept. 30 was $1.74 billion, up from $1.56 billion a year earlier. Analysts surveyed by Capital IQ expected $1.77 billion.
Intuitive Surgical Q3 Non-GAAP Earnings, Revenue Increase Read Post »
UBS analyst Trung Huynh assumes Eli Lilly (NYSE:LLY) with a Buy rating and raises Price Target to $710.
UBS raises Eli Lilly (NYSE:LLY) Price Target to $710 Read Post »
UBS analyst Colin Bristow assumes Pfizer (NYSE:PFE) with a Neutral rating and lowers Price Target of $34.
UBS lowers Pfizer (NYSE:PFE) Price Target of $34 Read Post »
Amgen (AMGN) on Friday said its global phase 2 study of tarlatamab in patients with advanced stage small cell lung cancer showed that the investigational drug delivered an “encouraging” objective response rate of 40% and median overall survival of 14.3 months. “In the current third-line treatment of SCLC, patients face a dire prognosis, with response rates ranging between 14 and 21 percent and median overall survival less than six months,” said Luis Paz-Ares, head of the lung cancer unit at the National Oncology Research Center. Amgen said no new safety concerns were reported and there were only 4% discontinuations due to treatment-related adverse events. Tarlatamab is an investigational drug targeting the BiTE, or bi-specific T-cell engager, molecule, directing them toward tumor-specific antigens, and activating their cytotoxic capabilities to eradicate cancer, according to the company.
Amgen Reports ‘Encouraging’ Results From Phase 2 Tarlatamab Study for Lung Cancer Read Post »
Wells Fargo analyst Larry Biegelsen maintains Intuitive Surgical (NASDAQ:ISRG) with a Overweight and lowers the price target from $386 to $363.
Wells Fargo lowers Intuitive Surgical (NASDAQ:ISRG) price target from $386 to $363 Read Post »
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target price to $306 from $395, 47.1x our 2024 EPS estimate, in line with ISRG’s historical forward average. We lift our EPS estimate for 2023 by $0.03 to $5.57 and for 2024 by $0.06 to $6.50. ISRG reported Q3 EPS of $1.46 versus $1.19, exceeding the S&P Capital IQ consensus estimate by $0.04. Results were driven by 19% Y/Y growth in da Vinci procedures globally, despite lower patient backlog than earlier in the year, with outside-U.S. procedures growth of 24% due to strength in India, Germany, the U.K., and Japan. Further, the installed base of da Vinci Systems grew 13% Y/Y and average system utilization expanded 6% in the quarter. We forecast full-year 2023 procedure growth of 21.5%, up 50 basis points from
CFRA Reiterates Buy Opinion On Shares Of Intuitive Surgical, Inc. Read Post »
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target price to $113 from $130, 24.4x our ’24 EPS forecast, in line with ABT’s historical forward average. We lift our ’23 EPS estimate by $0.03 to $4.43 and maintain our ’24 estimate of $4.63. Q3 adj. EPS of $1.14 vs. $1.15 beat the consensus view by $0.04, driven by sales growth from Nutrition (+16% Y/Y) due to continued market share recapture in the U.S. infant formula business, where ABT has now reclaimed the leadership position, in addition to growth in Medical Device sales (+17% Y/Y), aided by FreeStyle Libre sales growth of 28% in Q3. ABT sees a growing number of Libre users in the U.S. using Libre in combination with GLP-1 medications — a view that these approaches are complementary as
CFRA Keeps Buy Opinion On Shares Of Abbott Laboratories Read Post »
Intuitive Surgical, which makes robotic-surgery systems, says the rollout of weight-loss drugs like Ozempic is pressuring demand for bariatric surgeries in the short term, but the company expects those people to eventually opt for a weight-loss surgery. “In the short-term we will see patients who are considering or are in the pipeline for bariatric surgery going to try the drug,” Chief Medical Officer Myriam Curet tells analysts on a conference call. “However, given compliance issues, cost, side effects, we expect that many of them will not stay on the drugs for longer than a year or two, and at that time will consider bariatric surgery.” Longer term, Curet says the company expects interest in weight loss to grow and boost demand for surgeries. Shares slip 1.6%.
Intuitive Surgical Says Many Will Drop Weight-Loss Drugs, Opt for Surgery Read Post »
JPMorgan analyst Chris Schott reinstates Amgen (NASDAQ:AMGN) with a Neutral and announces $270 price target.
JPMorgan announces Amgen (NASDAQ:AMGN) $270 price target Read Post »